<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-6TB9AXI0</identifier><date>2024</date><creator>Ahlin Grabnar, Pegi</creator><creator>Gosenca Matjaž, Mirjam</creator><relation>documents/doc/6/URN_NBN_SI_doc-6TB9AXI0_001.pdf</relation><relation>documents/doc/6/URN_NBN_SI_doc-6TB9AXI0_001.txt</relation><format format_type="issue">2</format><format format_type="volume">75</format><format format_type="type">article</format><format format_type="extent">str. 94-104</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">196197635</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-6TB9AXI0</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="eng">biological medicinal products</subject><subject language_type_id="slv">Biološka zdravila</subject><subject language_type_id="eng">monoclonal antibodies</subject><subject language_type_id="slv">monoklonska protitelesa</subject><subject language_type_id="eng">peptides</subject><subject language_type_id="slv">peptidi</subject><subject language_type_id="eng">subcutaneous application</subject><subject language_type_id="slv">subkutana aplikacija</subject><title>Subkutana dostava terapevtskih proteinov in peptidov</title><title>Subcutaneous delivery of therapeutic proteins and peptides</title></Record>